Mallinckrodt
Also known as: Mallinckrodt | MALLINCKRODT | MALLINCKRODT ARD | MALLINCKRODT HOSP | Mallinckrodt, Inc. | MALLINCKRODT INC | MALLINCKRODT IRELAND | Mallinckrodt Pharma IP Trading DAC | Mallinckrodt (v1) | Mallinckrodt (v2) | MALLINKRODT NUCLEAR | Therakos, LLC, a Mallinckrodt Company
Highest phase reached
Phase 4
First clinical trial
Aug 1, 1998First marketed drug
Dec 15, 1947First NDA
May 24, 1968Last known activity
Jan 31, 2025
Timeline
1860s
- Jul 1, 1867
Mallinckrodt— Founded
1960s
- Jun 21, 1968
intrinsic factor— NDA Organization
1970s
- Dec 30, 1977
ultra-technekow fm— NDA Secondary Org
1980s
- Jan 1, 1982
Avon Products— Acquired By
- Jan 1, 1986
1990s
- Feb 12, 1996
Graham Dm— Acquired
2000s
- Aug 29, 2003
acetaminophen— Marketing Organization
Drugs by trial phase (45 distinct, 193 trials)
Phase 4 (17 own, 0 via acquisition)
Phase 3 (13 own, 0 via acquisition)
Phase 2 (9 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acidosis
- Acidosis, Respiratory
- Acute Chest Syndrome
- Acute Lung Injury
- Acute Pain
- Amyotrophic Lateral Sclerosis
- Anemia
- Anemia, Sickle Cell
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Back Pain
- Brain Diseases
- Bronchopulmonary Dysplasia
- Cardiomyopathies
- Cardiotoxicity
- Chronic Pain
- Communicable Diseases
- Crohn Disease
- Cystic Fibrosis
- Demyelinating Diseases
- Dermatomyositis
- Diabetic Foot
- Diabetic Nephropathies
- Dry Eye Syndromes
- Embolism
- Eye Diseases
- Familial Primary Pulmonary Hypertension
- Fatigue
- Fever
- Fibrosis
- Foot Ulcer
- Glomerulonephritis
- Glomerulonephritis, IGA
- Glomerulonephritis, Membranous
- Glomerulosclerosis, Focal Segmental
- Graft vs Host Disease
- Heart Arrest
- Heart Defects, Congenital
- Heart Diseases
- Heart Failure
- Hemorrhage
- Hepatic Encephalopathy
- Hepatorenal Syndrome
- Hernia, Ventral
- Hyperalgesia
- Hyperplasia
- Hypertension
- Hypertension, Pulmonary
- Hypoxia
- Infarction
- Infections
- Inflammation
- Iridocyclitis
- Ischemia
- Keratitis
- Keratoconjunctivitis Sicca
- Kidney Diseases
- Liver Cirrhosis
- Low Back Pain
- Lung Diseases
- Lung Injury
- Lung Neoplasms
- Lupus Erythematosus, Systemic
- Lupus Nephritis
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Macular Edema
- Malnutrition
- Motor Neuron Disease
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Muscle Spasticity
- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Mycobacterium Infections
- Mycobacterium Infections, Nontuberculous
- Mycoses
- Mycosis Fungoides
- Myocardial Infarction
- Neoplasm Metastasis
- Neoplasms
- Nephritis
- Nephrosis
- Nephrotic Syndrome
- Neuritis
- Optic Neuritis
- Osteoarthritis
- Osteoarthritis, Hip
- Osteoarthritis, Knee
- Out-of-Hospital Cardiac Arrest
- Pain
- Pancreatic Diseases
- Panuveitis
- Pars Planitis
- Pathologic Processes
- Persistent Fetal Circulation Syndrome
- Pneumonia
Marketed drugs (37)
- hydrocodone
- corticotropin
- oxycodone
- etidronic acid
- gadoversetamide
- cyanocobalamin
- imipramine
- methoxsalen
- nitric oxide
- pemoline
- acetaminophen
- caffeine
- intrinsic factor
- technetium tc-99m sestamibi
- radiolabeled albumin technetium Tc-99m albumin colloid kit
- technetium tc-99m sulfur colloid kit
- terlipressin
- xenon xe-133
- methadone
- propoxyphene
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT06646016Lead sponsorPhase 2Jan 31, 2025
- NCT06646016OfficialPhase 2Jan 31, 2025
- NCT05871606CollaboratorPhase 1Apr 30, 2024
- NCT06249633CollaboratorEarly Phase 1Feb 29, 2024
- NCT04986605CollaboratorPhase 2Mar 31, 2022
- NCT04996667CollaboratorPhase 2Nov 1, 2021
- NCT05680558CollaboratorPhase 2May 8, 2021
- NCT04216927CollaboratorPhase 3Jan 30, 2020
- NCT04128462Lead sponsorPhase 3Nov 30, 2019
- NCT04128462Study directorPhase 3Nov 30, 2019
- NCT04169061Lead sponsorPhase 4Sep 30, 2019
- NCT04169061Study directorPhase 4Sep 30, 2019
- NCT04080076CollaboratorPhase 4Sep 4, 2019
- NCT03727776CollaboratorEarly Phase 1Jul 31, 2019
- NCT05546047CollaboratorPhase 4Mar 14, 2019
Details
- Founded
- St Louis, MO, US Jul 1, 1867
- First NDA
- May 24, 1968
- Last known activity
- Jan 31, 2025
Designations held
- Priority review
Notes
Acquired by Avon in 1982 To International Minerals and Chemicals in 1986 To Tyco in 2000 Spun out as part of Covidien in 2007 Spun out of Covidien in 2011- Mallinckrodt Pharmaceuticals (http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=2004226) Acquired CNS Therapeutics - 2012 Acquired Cadence Pharma - 2014 Acquired Questcor - 2014 Acquired Ikaria - 2015 Acquired Therakos - 2015 Acquired Stratatech - 2016 Acquired Ocera Therapeutics - 2017 Acquired Sucampo - 2017